Scancell HoldingsSCNLF 20 EV-to-FCF is -19.53 as of Jun. 27, 2026. GuruFocus rates SCNLF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 333 Biotechnology companies, Scancell Holdings ranks worse than 300300% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Scancell Holdings's Enterprise Value is $261.84 Mil.
Scancell Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Oct. 2025 was $-13.41 Mil. Therefore, Scancell Holdings's EV-to-FCF for today is -19.53.
The historical rank and industry rank for Scancell Holdings's EV-to-FCF or its related term are showing as below:
SCNLF'
s EV-to-FCF Range Over the Past 10 Years
Min: -29.14 Med: -11.98 Max: -7.68
Current: -20.11
During the past 13 years, the highest EV-to-FCF of Scancell Holdings was -7.68. The lowest was -29.14. And the median was -11.98.
SCNLF's EV-to-FCF is ranked worse than 100% of 333
companies
in the Biotechnology industry
Industry Median: 14.65
vs SCNLF: -20.11
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Scancell Holdings's PE Ratio (TTM) for today is calculated as:
Scancell Holdings's share price for today is $0.2789.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Scancell Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2025 was $-0.008.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Scancell Holdings EV-to-FCF Related Terms
Scancell Holdings EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Scancell Holdings's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Scancell Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scancell Holdings EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scancell Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Scancell Holdings's EV-to-FCF falls into.
Scancell Holdings's current Enterprise Value is $261.84 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Scancell Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Oct. 2025 was $-13.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scancell Holdings (SCNLF) has a EV-to-FCF of -19.53 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Scancell Holdings and its competitors. According to the industry distribution chart, Scancell Holdings ranks #999999 out of 333 companies in the Biotechnology industry.
Is Scancell Holdings' EV-to-FCF too high?
Scancell Holdings' current EV-to-FCF is -19.53. Based on the distribution chart, Scancell Holdings ranks #999999 out of 333 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Scancell Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #999999 out of 333 companies for EV-to-FCF. This places Scancell Holdings in the lower half of its industry. The industry median EV-to-FCF is 14.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.65, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Scancell Holdings and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scancell Holdings's current EV-to-FCF is -19.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current EV-to-FCF of -19.53. The current EV-to-FCF is -19.53. Scancell Holdings' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current EV-to-FCF is -19.53 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
20GF Score
Get the complete analysis for SCNLF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNLF has been successfully added to your 
